Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Wheeling District 21 renews eminent domain threat for new preschool
Wheeling Township Elementary District 21 may restart eminent domain proceedings on a local landscaping company’s property,... -
How District 204 plans to move freshmen back to Neuqua Valley High School
Naperville’s Neuqua Valley High School will bring all four grade levels under one roof for the... -
Mount Prospect chief meeting with legislators amid license-plate reader controversy
Mount Prospect Police Chief Michael Eterno will meet with state legislators this week about out-of-state access...